208 related articles for article (PubMed ID: 32234975)
1. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
van der Lely AJ; Kuhn E; Muhammad A; Coopmans EC; Neggers SJ; Chanson P
Eur J Endocrinol; 2020 Jun; 182(6):D17-D29. PubMed ID: 32234975
[TBL] [Abstract][Full Text] [Related]
2. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
[TBL] [Abstract][Full Text] [Related]
4. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
7. Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs.
Chiloiro S; Giampietro A; Frara S; Bima C; Donfrancesco F; Fleseriu CM; Pontecorvi A; Giustina A; Fleseriu M; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31613969
[TBL] [Abstract][Full Text] [Related]
8. Brazilian multicenter study on pegvisomant treatment in acromegaly.
Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
[TBL] [Abstract][Full Text] [Related]
9. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
11. How to improve effectiveness of pegvisomant treatment in acromegalic patients.
Ragonese M; Grottoli S; Maffei P; Alibrandi A; Ambrosio MR; Arnaldi G; Bianchi A; Puglisi S; Zatelli MC; De Marinis L; Ghigo E; Giustina A; Maffezzoni F; Martini C; Trementino L; Cannavo S
J Endocrinol Invest; 2018 May; 41(5):575-581. PubMed ID: 29080965
[TBL] [Abstract][Full Text] [Related]
12. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
13. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
Franck SE; Korevaar TIM; Petrossians P; Daly AF; Chanson P; Jaffrain-Réa ML; Brue T; Stalla GK; Carvalho D; Colao A; Hána V; Delemer B; Fajardo C; van der Lely AJ; Beckers A; Neggers SJCMM
Eur J Endocrinol; 2017 Apr; 176(4):421-431. PubMed ID: 28100630
[TBL] [Abstract][Full Text] [Related]
14. How to Position Pasireotide LAR Treatment in Acromegaly.
Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
[TBL] [Abstract][Full Text] [Related]
15. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
17. The role of combination medical therapy in the treatment of acromegaly.
Lim DS; Fleseriu M
Pituitary; 2017 Feb; 20(1):136-148. PubMed ID: 27522663
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment in acromegaly.
Paisley AN; Trainer PJ
Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
20. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
